anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an application of cinnamic acid in preparing a medicine for treating bone marrow suppression caused by an anti-tumor medicine. The antineoplastic agent is cyclophosphamide. The content of cinnamic acid in the medicine is 6-24 mg/kg. The invention uses the cinnamic acid for the bone marrow suppression caused by the antineoplastic medicine cyclophosphamide for the first time. The result shows that the cinnamic acid can increase the number of leucocytes and platelets in peripheral blood of a mouse and relieve the peripheral hemogram reduction caused by cyclophosphamide; the number of bone marrow nucleated cells of the mouse can also be increased. The cinnamic acid is proved to have the protective effect on the myelosuppression caused by cyclophosphamide, and a new idea is provided for the prevention and treatment of the myelosuppression caused by the antitumor drug.
Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
The invention belongs to the technical field of biological medicines, and particularly relates to a sesquiterpene compound and a preparation method and application thereof. The sesquiterpenoids provided by the invention are secondary metabolites of Bai Bachi bacteria (Irpex lacteus), and the chemical structure of the sesquiterpenoids is determined by nuclear magnetic resonance hydrogen spectrum, carbon spectrum and high-resolution mass spectrum, and the chemical name is as follows: ((6S, 6aS,8S,9aR, Z) -6,8-dimethyl-3-oxo-1,3,4,5, 6a,7,8,9 a-decahydroazulo [4, 5-c)]Furan-8-yl) methyl acetate, the chemical structure is as follows: meanwhile, a corresponding preparation method is also established, namely: culturing Rake fungus with liquid culture medium of fungus No. two for 25 days at room temperature, crushing mycelium after fermentation, mixing with fermentation broth, extracting with ethyl acetate of 2 times volume for 3-5 times, and concentrating the extractive solution under reduced pressure to obtain crude extract of Rake fungus. The crude extract of the Rake is subjected to column chromatography and semi-preparative liquid chromatography to obtain the compound 1. The compound is determined to be a new sesquiterpenoid compound through database screening comparison, and is separated from the fermentation product of the white harrow teeth for the first time. The lipid-lowering activity experiment shows that the compound 1 has the activity of reducing TG and the effect is superior to that of a positive medicine (lovastatin). Therefore, the sesquiterpene compound 1 has great development potential in medicinal or non-medicinal lipid-lowering and TG-lowering aspects.
PCT No. PCT/US96/13873 Sec. 371 Date Jun. 2, 1998 Sec. 102(e) Date Jun. 2, 1998 PCT Filed Aug. 29, 1996 PCT Pub. No. WO97/08328 PCT Pub. Date Mar. 6, 1997This invention provides compositions and methods for the elimination of T cells that recognize specific preselected targets. The methods involve providing killer cells (e.g. natural killer cells or cytotoxic T lymphocytes) having a T cell receptor in which the zeta chain is joined to the antigen target of the T cell population it is desired to eliminate. Recognition of the antigen target activates the killer cell thereby inhibiting or destroying the T cell. Where the antigen target is the extracellular domain of a major histocompatibility complex, the method provides a means of mitigating graft rejection or an autoimmune response.
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Multiple Myeloma Research Foundation's Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study ( NCT01454297 ) is a longitudinal, observational clinical study of newly diagnosed patients with multiple myeloma (n = 1,143) where tumor samples are characterized using whole-genome sequencing, whole-exome sequencing and RNA sequencing at diagnosis and progression, and clinical data are collected every 3 months. Analyses of the baseline cohort identified genes that are the target of recurrent gain-of-function and loss-of-function events. Consensus clustering identified 8 and 12 unique copy number and expression subtypes of myeloma, respectively, identifying high-risk genetic subtypes and elucidating many of the molecular underpinnings of these unique biological groups. Analysis of serial samples showed that 25.5% of patients transition to a high-risk expression subtype at progression. We observed robust expression of immunotherapy targets in this subtype, suggesting a potential therapeutic option.
Geriatric Use. Clinical studies of DEMEROL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be low, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See DOSAGE AND ADMINISTRATION.)

Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of DEMEROL and observed closely.

This drug is known to be excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Clinical studies indicate that differences in various pharmacokinetic parameters may exist between elderly and younger patients. (See CLINICAL PHARMACOLOGY.)
A carrot cane jelly and a manufacturing method for the carrot cane jelly relate to a health food and the manufacturing method for the food. The invention relates to a health food with the advantages of good taste and convenient eating, which can carry through industrial production. The manufacturing method is: the preparation of a colla corii asini wine solution is as following: heating the follow components according to the weight portion of 10 to 20 portions of colla corii asini, 20 to 30 of yellow wine to 60 to 80 DEG C and then preserving heat and mixing for 2 hours. The carrot is beaten to get a carrot slurry and the cane is squeezed to get a cane juice according to the weight portion of 10 to 20 portions of the carrot and 40 to 60 portions of the cane; the preparation of the carrot cane jelly: cooling the colla corii asini wine solution to 20 to 25 DEG C and adding the carrot cane slurry into the colla corii asini wine solution gradually and cooling to the normal temperature and pouring the cooled solution into a die to form a gel shape. The invention comprises the colla corii asini, the carrot and the cane and has the supply function of the colla corii asini, and also comprises various vitamins and minerals. The invention has sweet and sour flavor with the fragrance of wine and is a health food with high quality.
Promethazine HCl Injection can cause severe chemical irritation and damage to tissues, regardless of the route of administration. Irritation and damage can also result from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. 

Signs, symptoms, and manifestations of severe tissue irritation include burning, pain, erythema, swelling, severe spasm of distal vessels, thrombophlebitis, venous thrombosis, phlebitis, abscesses, tissue necrosis, and gangrene. Administration of Promethazine HCl Injection has resulted in nerve damage ranging from temporary sensory loss to palsies and paralysis. Injection into or near a nerve may result in permanent tissue damage. In some cases, surgical intervention (including fasciotomy, skin graft, and/or amputation) may be required (see ADVERSE REACTIONS).
Patients can be helped to break free of addictive or habit-forming narcotics and anti-depressants, by treatment using two drugs. One drug is dextromethorphan (DM), which has been used for decades as an anti-tussive (cough-suppressing) drug in cough syrups. The other drug is an oxidase inhibitor which suppresses activity of a liver enzyme called cytochrome P450-2D6 (also called debrisoquin hydroxylase, sparteine monooxygenase, cytochrome P450-DB, and CYP2D6). In most patients, this oxidase enzyme rapidly degrades DM and converts it into a metabolite called dextrorphan. An oxidase inhibitor (such as quinidine) which suppresses cytochrome P450-2D6 activity increases the half-life and concentration of DM in the circulating blood. When this combined treatment was administered orally to patients who had become dependent on morphine and anti-depressant drugs because of chronic intractable pain, it initially helped the patients reduce their dosages of morphine and other drugs, including anti-depressants. When additional testing was done, the combined treatment allowed patients to entirely terminate all use of morphine and anti-depressants, with minimal withdrawal or other adverse effects. Importantly, these same patients received no substantial benefit from taking dm by itself, without an oxidase inhibitor. Accordingly, the combination of dextromethorphan plus an anti-oxidase drug can allow at least some patients to break entirely free of narcotics and/or anti-depressants, even after years of use for chronic pain and other medical problems, even when they are not substantially helped by dextromethorphan alone.
For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
This disclosure is related to an intelligent Long-Term Care information transmission system, which is applicable to a Long-Term care center or a home care. The intelligent Long-Term Care information transmission system includes at least one intelligent service device, at least one service communication devices, a main service communication device and a server host. The intelligent service device is a wearable device for wearing on the elder or patient in this application. This disclosure proposed, is not only a wearable intelligent service device with a physiological information sensing, but also utilizes the wireless radio frequency identification (RFID) technology as well as Bluetooth mesh network transmission. With the devices disclosed in this invention, building a dedicated wireless transmitting network is no longer needed to transfer the physiological information into data system to reduce the working hours of the medical staff. It can be further applied to a long-term care institution or a home care center.
Participants will receive 20 sessions of sham tACS paired with working memory training. After unblinding (by someone from our lab but external to the study), they will receive 20 sessions of in-phase offline theta tACS.
BACKGROUND: Major emergency abdominal surgery is associated with a high risk of morbidity and mortality. Given the ageing and increasingly frail population, understanding the impact of frailty on complication patterns after surgery is crucial. The aim of this study was to evaluate the association between clinical frailty and organ-specific postoperative complications after major emergency abdominal surgery.
METHODS: A prospective cohort study including all patients undergoing major emergency abdominal surgery at Copenhagen University Hospital Herlev, Denmark, from 1 October 2020 to 1 August 2022, was performed. Clinical frailty scale scores were determined for all patients upon admission and patients were then analysed according to clinical frailty scale groups (scores of 1-3, 4-6, or 7-9). Postoperative complications were registered until discharge.
RESULTS: A total of 520 patients were identified. Patients with a low clinical frailty scale score (1-3) experienced fewer total complications (120 complications per 100 patients) compared with patients with clinical frailty scale scores of 4-6 (250 complications per 100 patients) and 7-9 (277 complications per 100 patients) (P < 0.001). A high clinical frailty scale score was associated with a high risk of pneumonia (P = 0.009), delirium (P < 0.001), atrial fibrillation (P = 0.020), and infectious complications in general (P < 0.001). Patients with severe frailty (clinical frailty scale score of 7-9) suffered from more surgical complications (P = 0.001) compared with the rest of the cohort. Severe frailty was associated with a high risk of 30-day mortality (33% for patients with a clinical frailty scale score of 7-9 versus 3.6% for patients with a clinical frailty scale score of 1-3, P < 0.001). In a multivariate analysis, an increasing degree of clinical frailty was found to be significantly associated with developing at least one complication.
CONCLUSION: Patients with frailty have a significantly increased risk of postoperative complications after major emergency abdominal surgery, especially atrial fibrillation, delirium, and pneumonia. Likewise, patients with frailty have an increased risk of mortality within 90 days. Thus, frailty is a significant predictor for adverse events after major emergency abdominal surgery and should be considered in all patients undergoing major emergency abdominal surgery.
Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
This is a randomized controlled trial of an internet-based intervention to increase physical activity in persons with multiple sclerosis. Multiple sclerosis (MS) is the most common non-traumatic neurological cause of disability in young adults. Sedentary behavior, now recognized as a major contributor to increased morbidity is seen at higher rates and related to adverse health outcomes for persons with MS (PwMS). Prominent symptoms of MS (motor impairment, fatigue, depressed mood, pain), place this population at unique risk for increased sedentary behavior. And importantly, with increased age comes increased risk: patients over 60 are significantly more sedentary than middle-aged patients. On a positive note, current disease modifying therapies prolong time to disease progression, widening the window of opportunity for implementing behavioral interventions that support health and successful aging. Behaviors adopted early in life are more likely to be maintained into later adulthood. Physical activity is beneficial for PwMS on multiple levels: improved gait and balance, improved cognition, reduced depression and fatigue. Finding ways to increase physical activity is a key research priority for MS. Behavioral change is difficult to adopt and even more difficult to maintain. Here, we introduce a novel behavioral intervention to increase physical activity, eFIT, a technology-enabled (i.e., internet-delivered) support group-based treatment that leverages accountability to motivate and sustain behavioral change. Accountability constitutes the bedrock underlying the single most pervasive, successful, and widely embraced behavioral intervention known: Alcoholics Anonymous (AA). Through sponsors and support groups, AA utilizes accountability partners to deliver, reinforce, and sustain life-saving behavioral change. Here, we leverage accountability partners to motivate enduring behavioral change in physical activity participation, one of the single most difficult health behaviors to implement and maintain.
The invention discloses an anti-aging composition, eye cream and a preparation method thereof. In a first aspect of the present application, there is provided a composition comprising retinol, biological placental peptide, and hydroxypropyl tetrahydropyrane triol. The compositions according to embodiments of the present application have at least the following benefits: the components in the formula are reasonably compatible and have synergistic effect. The nano retinol is used as a main material, the efficacy combination of the biological placenta and the hydroxypropyl tetrahydropyrane triol is compounded, and the effects of resisting aging and tightening are achieved. Wherein, the retinol has good anti-aging effect. The hydroxypropyl tetrahydropyrane triol can enable the skin to synthesize hyaluronic acid by itself, and keep the water tenderness and the surface gloss of the skin. The biological placenta extract is prepared by biological fermentation, contains multiple growth factors, has the same components as human placenta, and can better permeate skin to play a role. The three components are mutually blended and have synergistic effect, and the wrinkle removing and skin elasticity restoring effects are very outstanding.
FIELD: medicine. ^ SUBSTANCE: vaccine strain of B/60/Brisbane/08/83 (H1N1) influenza virus is a reassortant prepared by cross breeding an epidemic B/Brisbane/60/2008 virus and a cold-adapted thermally sensitive B/USSR/60/69 (H2N2) virus being a human-safe attenuation donor. The B/60/Brisbane/08/83 strain replicates actively in growing chicken embryos at optimum temperature 32C. The strain is characterised by thermal sensitivity and cold adaptation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. The B/60/Brisbane/08/83 strain is areactogenic for adults and children in intranasal introduction. In reactogenecity, the vaccine strain of B/60/Brisbane/08/83 influenza virus meets the requirements specified in the Manufacturer's Monograph 42-0504-4097-04 to vaccine strains for live dry allantoic influenza vaccine for intranasal application. ^ EFFECT: improved strain characteristics. ^ 4 tbl, 2 ex
Hearing loss is a major health concern in our society, affecting more than 400 million people worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss in 40% to 60% of patients receiving treatment, and despite these high numbers, no drug for preventing or treating this type of hearing loss has yet been approved by the US Food and Drug Administration. We have previously conducted high-throughput screenings of bioactive compounds, using zebrafish as our discovery platform, and identified piplartine as a potential therapeutic molecule. In the present study, we expanded this work and characterized piplartine's physicochemical and therapeutic properties. We showed that piplartine had a wide therapeutic window and neither induced nephrotoxicity in vivo in zebrafish nor interfered with aminoglycoside antibacterial activity. In addition, a fluorescence-based assay demonstrated that piplartine did not inhibit cytochrome C activity in microsomes. Coadministration of piplartine protected from kanamycin-induced hair cell loss in zebrafish and protected hearing function, outer hair cells, and presynaptic ribbons in a mouse model of kanamycin ototoxicity. Last, we investigated piplartine's mechanism of action by phospho-omics, immunoblotting, immunohistochemistry, and molecular dynamics experiments. We found an up-regulation of AKT1 signaling in the cochleas of mice cotreated with piplartine. Piplartine treatment normalized kanamycin-induced up-regulation of TRPV1 expression and modulated the gating properties of this receptor. Because aminoglycoside entrance to the inner ear is, in part, mediated by TRPV1, these results suggested that by regulating TRPV1 expression, piplartine blocked aminoglycoside's entrance, thereby preventing the long-term deleterious effects of aminoglycoside accumulation in the inner ear compartment.
SIGNIFICANCE STATEMENT: ESKD incidence has changed substantially in the past four decades, but differences by age and race have been unexplored. Using data from the United States Renal Data System, we found that ESKD incidence rose for Black and White teenagers, adults, and older adults for two decades beginning in 1980. Growth in incidence slowed for most groups by 1993, and by 2006, the annual percent change (APC) in ESKD incidence had declined for all groups, except White adults, for whom rates continued to rise. By 2019, ESKD incidence among Black and White adolescents nearly returned to 1980 levels, but no other group achieved that degree of improvement. Nonetheless, the ESKD incidence rate among Black American patients exceeds that of White patients in every age group. Distinct patterns in ESKD incidence among patients of different age, sex, and racial groups are shown. These findings could reflect changes in dialysis acceptance rates, access to preventive health care, incidence of diabetes mellitus, implementation of evidence-based guidelines for treatment of CKD, or other unrecognized factors. There may be population-specific opportunities to change the growth of the US ESKD population and address current racial disparities.
BACKGROUND: Substantial changes in ESKD incidence over four decades among Black and White Americans of different ages have been incompletely explored.
METHODS: We analyzed United States Renal Data System data from 1980 to 2019 to determine ESKD incidence trends among Black and White adolescent (13-17 years), adult (18-64 years), and older adult (≥65) populations. We used the National Cancer Institute Joinpoint Regression Program to estimate annual percent change (APC) in ESKD incidence and to define points in time where a statistically significant change in APC slope occurred for each group.
RESULTS: ESKD incidence rose after 1980 for all groups, although the trends differed ( P < 0.001). Growth in incidence slowed for most by 1993, and by 2006, the APC in ESKD incidence had declined for all groups, except White adults, for whom rates continued to rise ( P < 0.05). By 2019, ESKD incidence among Black and White adolescents nearly returned to 1980 levels, but no other group achieved that degree of improvement. Nonetheless, the ESKD incidence among Black American patients exceeds that of White patients in every age group.
CONCLUSIONS: Distinct patterns in ESKD incidence among patients of different age, sex, and racial groups are shown. These findings could reflect changes in dialysis acceptance rates, access to preventive health care, incidence of diabetes mellitus, implementation of evidence-based guidelines for treatment of CKD, or other unrecognized factors.
PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_03_13_ASN0000000000000310.mp3.